Quadrant Capital Group’s Sana Biotechnology SANA Stock Holding History

Quadrant Capital Group’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.26K	Hold	1,480	–	–	﹤0.01%	2388
2025 Q4	$6.02K	Hold	1,480	–	–	﹤0.01%	2326
2025 Q3	$5.25K	Buy	+1,480	New	+$5.35K	﹤0.01%	2317
2025 Q2	–	Sell	-2,068	Closed	-$3.48K	–	2367
2025 Q1	$3.48K	Buy	2,068 +1,220	+144%	+$3.41K	﹤0.01%	2429
2024 Q4	$1.38K	Buy	848 +56	+7%	+$167	﹤0.01%	2546
2024 Q3	$3.29K	Hold	792	–	–	﹤0.01%	2407
2024 Q2	$4.33K	Hold	792	–	–	﹤0.01%	2333
2024 Q1	$7.92K	Hold	792	–	–	﹤0.01%	2182
2023 Q4	$3.23K	Buy	792 +321	+68%	+$1.18K	﹤0.01%	2373
2023 Q3	$1.82K	Hold	471	–	–	﹤0.01%	2412
2023 Q2	$2.81K	Hold	471	–	–	﹤0.01%	2341
2023 Q1	$1.54K	Sell	471 -30	-6%	-$120	﹤0.01%	2473
2022 Q4	$1.98K	Buy	501 +471	+1,570%	+$2.3K	﹤0.01%	2419
2022 Q3	$0	Hold	30	–	–	﹤0.01%	2786
2022 Q2	$0	Sell	30 -1	-3%	-$6	﹤0.01%	2705
2022 Q1	$0	Buy	+31	New	+$251	﹤0.01%	2671

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Quadrant Capital Group's SANA Position: Q1 2026 in Review

Quadrant Capital Group held its Sana Biotechnology (SANA) position steady in Q1 2026 at 1,480 shares worth $4.26K. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Quadrant Capital Group first reported a position in SANA in Q1 2022 and has held it in 16 quarters since. The position peaked at $7.92K in Q1 2024. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

Quadrant Capital Group held 1,480 shares of Sana Biotechnology worth $4.26K as of Q1 2026.
Quadrant Capital Group left its Sana Biotechnology share count unchanged in Q1 2026.
Sana Biotechnology made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2388 holding.
Quadrant Capital Group first reported a position in Sana Biotechnology in Q1 2022 and has held it in 16 quarters since.
Quadrant Capital Group's Sana Biotechnology position peaked at $7.92K in Q1 2024.
202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.